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Abstract
Introduction: Development of a sarcomatous component in a germ cell tumor is an uncommon phenomenon.
Most cases reported have a grim prognosis. Growing teratoma syndrome is also an uncommon phenomenon and
occurs in approximately 2% to 7% of non seminomatous germ cell tumors and should be treated surgically.
Case presentation: We report the case of a 12-year-old Asian girl with an ovarian mixed germ cell tumor
containing a rhabdomyosarcomatous component. She was treated with a germ cell tumor chemotherapy regimen
and rhabdomyosarcoma-specific chemotherapy. Towards the end of her treatment, she developed a
retroperitoneal mass that was increasing in size. It was completely resected, revealing a mature teratoma,
consistent with growing teratoma syndrome. She is still in complete remission approximately three years after
presentation.
Conclusion: The presence of rhabdomyosarcoma in a germ cell tumor should be treated by a combined
chemotherapy regimen (for germ cell tumor and rhabdomyosarcoma). In addition, development of a mass during
or after therapy with normal serum markers should raise the possibility of growing teratoma syndrome that should
be treated surgically.
Introduction
Development of a sarcomatous component (SC) in a
germ cell tumor (GCT) is a rare phenomenon. Many
histologic types of SC are described which can be pre-
sent in the primary tumor or in the metastatic sites.
T h ep r e s e n c eo fs a r c o m a sw i t h i nG C T si sm o s t l y
encountered in testicular and mediastinal GCT while
their presence in an ovarian GCT has rarely been
reported. Meticulous histological examination is very
important to determine the type and percentage of SC
within a GCT as this affects prognosis. Growing tera-
toma syndrome (GTS) is also a rarely reported phenom-
enon. It was first described in 1982 [1] and occurs in
approximately 2% to 7% of non-seminomatous germ cell
tumors (NSGCT) [2,3]. It requires three criteria for
definition: firstly, normalization of the previously ele-
vated serum tumor markers (alpha fetoprotein (AFP)
and beta human chorionic gonadotropins (B-HCG));
secondly, an increase in tumor size during and after
chemotherapy given for NSGCT; and thirdly, the
absence of any NSGCT component other than mature
teratoma (MT) when the tumor is resected. Another
characteristic finding of the GTS is the appearance of
cysts within the growing masses which appear as an
increase in mass size.
The patient’s primary tumor histopathology, her
response to chemotherapy, and development of rare
GTS make this patient’s case worth reporting.
Case presentation
A 12-year- old Asian girl presented with lower abdom-
inal pain and distension of two months duration. A
non-tender abdominal mass was found by palpation.
Past medical history was unremarkable. She had not had
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showed a huge, heterogeneously enhancing pelviabdom-
inal mass with multiple cystic and necrotic areas, origi-
nating from the right ovary (Figure 1A). The results of
alpha fetoprotein (AFP) and beta human chorionic
gonadotropin (B-HCG) laboratory tests were both ele-
vated (2793 ng/ml (normal < 10) and 27361 mIU/ml
(normal < 2), respectively). She underwent laparotomy
with removal of the mass, right salpingoopherectomy,
partial omentectomy, iliac lymph nodes sampling, and
ascetic fluid sampling. No intraoperative spillage was
observed. Histopathology revealed non-germinomatous
m i x e dg e r mc e l lc o m p o s e do fam i x t u r eo fy o l ks a c
tumor (20%), mature teratoma (30%) (Figure 2A),
embryonal carcinoma (40%), and choriocarcinoma (5%).
In addition, an embryonal rhabdomyosarcomatous
component (5%) (Figure 2B) was identified in the form
of spindle and globoid rhabdomyoblasts staining posi-
tively with desmin and focally for myogenin. Iliac lymph
nodes, omentum, and peritoneal excisional biopsies
were free of tumor. Ascetic fluid cytology was also free
of malignancy.
She was treated with eight courses of chemotherapy
(Table 1). She was followed by serial AFP and B-HCG
tests which both normalized after the third cycle of
chemotherapy.
Six months after presentation and while she was on
chemotherapy a right hypochondrial mass was detected
by physical examination. Imaging studies revealed a new
complex multiloculated mass in the right suprarenal
area (Figure 1B). Serum markers were normal. Compu-
terized tomography-guided biopsy revealed a mature
Figure 1 Computerized Tomography findings before and during the course of treatment.( A1) showing huge heterogeneous mass filling
the upper pelviabdominal cavity (arrows), (A2) showing unremarkable pelvis after chemotherapy, (B) showing the appearance of a new mass
situated between right liver lobe, right kidney, and adrenal gland (arrows).
Figure 2 Histological features of the primary ovarian mass and the recurrent new mass.( A) low power magnification of the mature
teratoma component, in which mature glands and stroma are seen (H&E X4), (B): higher power magnification of rhabdomyoblasts seen with
abundant acidophilic cytoplasm and eccentric nuclei (H&E X 40) (inset show desmin positive staining of the rhabdomyoblasts), (C): mature
glandular tissue is seen in the recurrent new mass, no immature tissue was identified (H&E X 40).
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the mass. She then underwent laparotomy with com-
plete resection of the mass. Histopathology confirmed
the presence of mature cystic teratoma (Figure 2C).
She is still in complete remission 32 months after
presentation.
Discussion
We describe an ovarian mixed GCT with rhabdomyo-
sarcomatous components and elevated serum AFP and
B-HCG in an adolescent girl. The development of SC in
GCT is an uncommon phenomenon. Histologic types of
SC reported in the literature are the following: rhabdo-
myosarcoma, high grade unclassified sarcoma, rhabdo-
myosarcoma admixed with high-grade unclassified
sarcoma, angiosarcoma, and low-grade myxoid sarcoma
[4-7]. The sarcomatous element can be present in the
primary tumor or it can appear in the metastases [7].
The occurrence of sarcomas within GCTs has mostly
been encountered in testicular and mediastinal GCT
while their presence in an ovarian GCT has rarely been
reported [7-10]. The sarcomatous component is of para-
mount importance because of its aggressive behavior,
tendency for metastasis, and poor prognosis and thus
may support the inclusion of sarcoma-oriented drugs
for this particular group [8]. The proportion of SC
within germ cell tumors appears to have influenced the
prognosis (that is, the higher the percentage of SC
within GCT the poorer the prognosis) [11]. So the
importance of thorough sampling and meticulous histo-
logical examination for determining the type and extent
of the malignant component should be emphasized.
The largest study was published by Malagon et al.
They identified 46 cases of GCT with SC. Rhabdomyo-
sarcomatous (RMS) components were found in 28 cases.
Only two patients were in the pediatric age group.
Details of treatment were not reviewed, however most
patients were treated recently, suggesting the use of
multimodality treatment. Nevertheless, the outcome of
these patients appeared to be less than favorable [8].
Although the pathogenesis of the development of sar-
comatous components in GCT has not been fully eluci-
dated, origins proposed have included dedifferentiation
or malignant transformation of certain mesenchymal
components within teratomas, origin from primitive
germ cells or transformation of the blastematous stroma
in yolk sac tumor [7,8,12]. Upon review of the literature
it is clear that most GCT with SC (whether in the pri-
mary tumor or in the metastases) have a teratoma com-
ponent as well, which might support the first theory
[12]. Noteworthy is the notion that the old terminology
of the World Health Organization (WHO) classification
of the presence of non-germ cell malignancies within
germ cell neoplasms was ‘teratoma with malignant
transformation’ or ‘teratoma with malignant areas’ [13].
GTS is a very rare phenomenon. Prognosis is favor-
able when surgery is radical [1,3]. Otherwise the out-
come may be grim [14]. Our patient fulfilled the criteria
of GTS and so was treated with radical resection only.
Although GTS is mostly reported in adults, we have
identified some pediatric cases (Table 2) [15-19].
The pathogenesis of the GTS is still unclear but two
mechanisms have been considered: malignant cell differ-
entiation into mature teratoma (MT) or a chemother-
apy-induced destruction of the component other than
mature teratoma (that is, the killing of malignant cells
by chemotherapy with concomitant MT enlargement)
[20]. As our patient had a rhabdomyosarcomatous com-
ponent in the initial histology, we are more in favor of
the second mechanism.
Successful pregnancy after development of GTS has
been reported indicating the necessity of a fertility spar-
ing surgical approach in the treatment of young female
patients [21].
Many factors have been proposed that might predict
the subsequent development of a GTS including the fol-
lowing: presence of MT in the primary NSGCT; no
reduction in the size of metastases during chemother-
apy; and the presence of MT in post chemotherapy resi-
dual masses [20].
Clinical complications associated with GTS were esti-
mated as approximately 12% and generally related to
organ compression [20]. Malignant transformation may
occur as well, albeit at a much lower rate (3%) [20] and
tends to be encountered more in adults. This includes
transformation into malignant NSGCT, sarcoma, squa-
mous cell carcinoma, adenocarcinoma, carcinoid tumor
and primitive neuroectodermal tumor (PNET).
Alpha-interferon therapy has been reported as an
option for treatment of recurrent mature teratoma
although it was not confirmed in a cohort of patients
Table 1 Courses of chemotherapy used by the patient
Chemotherapy course number Week Chemotherapeutic agents
1 0 BEP
2 three VAC
3 six BEP
4 nine BEP
5 12 BEP
6 15 BEP
7 18 BEP
8 21 VAC
9 24 VAC
10 27 VAC
BEP, Bleomycin, Etoposide, Cisplatin; VAC, Vincristine, Actinomycin, and
Cyclophosphamide
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dependent kinase CDK inhibitors suggests a new treat-
ment for growing teratoma syndrome especially in those
with unresected or recurrent GTS [23].
Conclusions
We report a rare case of an ovarian mixed GCT asso-
ciated with a rhabdomyosarcomatous component which
was treated successfully using a combined regimen (for
GCT and RMS). The case was also complicated by the
occurrence of the GTS which was treated surgically.
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